Lv1
80 积分 2020-10-14 加入
Sex differences in LDL-C response to PCSK9 inhibitors: A real world experience
22小时前
已完结
Efficacy and safety of cadonilimab, an anti-PD-1/CTLA4 bi-specific antibody, in previously treated recurrent or metastatic (R/M) cervical cancer: a multicenter, open-label, single-arm, phase II trial (075)
27天前
已完结
Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial
1个月前
已完结
Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer
2个月前
已完结
Recaticimab Monotherapy for Nonfamilial Hypercholesterolemia and Mixed Hyperlipemia
2个月前
已完结
Real-world experience with mavacamten in obstructive hypertrophic cardiomyopathy: Observations from a tertiary care center
3个月前
已完结
Real-world experience with mavacamten in obstructive hypertrophic cardiomyopathy: Observations from a tertiary care center
3个月前
已完结
Cemiplimab as Second-Line Therapy for Patients with Recurrent Cervical Cancer: A United States-based Cost-effectiveness Analysis
4个月前
已完结
Postmarketing Reports of Incomplete Dosing-Related Complications with Self-Injected PCSK9 Inhibitors: A Descriptive Study and Disproportionality Analysis
4个月前
已完结
Multi-organ immune-related adverse events from immune checkpoint inhibitors and their downstream implications: a retrospective multicohort study
4个月前
已完结
皖公网安备34019202002308
